Healthcare of Ontario Pension Plan Trust Fund Purchases Shares of 221,595 Celcuity, Inc. $CELC

Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Celcuity, Inc. (NASDAQ:CELC) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 221,595 shares of the company’s stock, valued at approximately $22,102,000.

Other institutional investors have also modified their holdings of the company. EverSource Wealth Advisors LLC grew its holdings in shares of Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after purchasing an additional 319 shares during the period. US Bancorp DE grew its holdings in shares of Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after purchasing an additional 143 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after purchasing an additional 1,167 shares during the period. Meeder Asset Management Inc. purchased a new stake in shares of Celcuity during the 4th quarter worth about $42,000. Finally, Ogorek Anthony Joseph NY ADV grew its holdings in shares of Celcuity by 19.7% during the 4th quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock worth $66,000 after purchasing an additional 109 shares during the period. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Insider Activity at Celcuity

In related news, Director David Dalvey sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the transaction, the director directly owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. The trade was a 27.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the transaction, the director directly owned 6,760 shares in the company, valued at $949,509.60. This trade represents a 57.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 37,000 shares of company stock worth $5,111,950 over the last three months. 13.33% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Leerink Partners set a $155.00 target price on Celcuity in a report on Tuesday, June 2nd. Guggenheim reiterated a “buy” rating on shares of Celcuity in a report on Wednesday, June 3rd. Wolfe Research reiterated an “outperform” rating and set a $110.00 target price on shares of Celcuity in a report on Thursday, March 12th. Citizens Jmp boosted their target price on Celcuity from $150.00 to $160.00 and gave the stock a “market outperform” rating in a report on Monday, May 4th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $157.00 target price on shares of Celcuity in a report on Friday, May 15th. Eleven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Celcuity has an average rating of “Moderate Buy” and a consensus price target of $152.09.

Celcuity Stock Performance

Celcuity stock opened at $88.24 on Tuesday. The stock’s 50 day moving average price is $119.32 and its 200 day moving average price is $111.22. The firm has a market capitalization of $4.30 billion, a PE ratio of -22.63 and a beta of 0.10. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. Celcuity, Inc. has a one year low of $11.27 and a one year high of $151.02.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.10. As a group, sell-side analysts expect that Celcuity, Inc. will post -3.69 EPS for the current fiscal year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.